Literature DB >> 7570434

Hormonal, renal, and autonomic nerve factors involved in the excretion of sodium and water during dynamic salt and water loading in hypoxaemic chronic obstructive pulmonary disease.

A G Stewart1, J C Waterhouse, C G Billings, P H Baylis, P Howard.   

Abstract

BACKGROUND: Some patients with hypoxaemic chronic obstructive pulmonary disease (COPD) develop sodium and water retention and a subclinical autonomic neuropathy. The possibility that these might be associated has been investigated.
METHODS: The ability of 24 patients with COPD to excrete a 6 ml/kg 2.7% intravenous saline or 15 ml/kg oral water load was studied and changes in plasma electrolyte levels, osmolality, plasma aldosterone and vasopressin levels, urinary volume and sodium content, glomerular filtration rate, renal blood flow, and cardiovascular autonomic nerve function were measured. Patients were divided into groups of eight: those in group A (controls) had mild COPD with a Pa02 of > 9 kPa and no oedema, patients in group B were more hypoxaemic but had never been oedematous, whilst those in group C were hypoxaemic and mildly oedematous at the time of the study.
RESULTS: Patients in groups B and C excreted less sodium and water during saline loading and a lesser proportion of the water load. Patients in group C had a reduction in renal blood flow and glomerular filtration rate and all had a subclinical autonomic neuropathy, which was also found in three patients in group B. Their plasma aldosterone level was raised but did suppress appropriately on saline loading. Vasopressin levels were abnormally raised for the osmolality in patients in group C and in those with autonomic dysfunction throughout the water load and at 240 minutes after the salt load. Sodium and urine excretion was highly correlated with autonomic dysfunction, aldosterone levels at time zero, and renal blood flow. The 11 patients with autonomic dysfunction were more likely to be oedematous, more hypoxaemic, excreted much less urine and sodium, had lower glomerular filtration rate and renal blood flow, and higher aldosterone and vasopressin levels than the remaining patients.
CONCLUSIONS: In patients with COPD the inability to excrete sodium and water is multifactorial. This is the first study to show that autonomic dysfunction is at least associated and might play an important part in the impaired sodium and water homeostasis seen in patients with severe COPD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7570434      PMCID: PMC474898          DOI: 10.1136/thx.50.8.838

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  33 in total

1.  An explanation for and experimental correction of the abnormal water diuresis in cirrhosis.

Authors:  H P SCHEDL; F C BARTTER
Journal:  J Clin Invest       Date:  1960-02       Impact factor: 14.808

2.  Role of vagal neuropathy in the hyponatraemia of alcoholic cirrhosis.

Authors:  G Decaux; P Cauchie; A Soupart; M Kruger; F Delwiche
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-13

3.  Effect of beta adrenergic blockade on renin response to renal nerve stimulation.

Authors:  M S Taher; L G McLain; K M McDonald; R W Schrier; L K Gilbert; G A Aisenbrey; A L McCool
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

Review 4.  The Veterans Administration cooperative study of pulmonary function. 3. Mortality in relation to respiratory function in chronic obstructive pulmonary disease.

Authors:  A D Renzetti; J H McClement; B D Litt
Journal:  Am J Med       Date:  1966-07       Impact factor: 4.965

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  The effects of angiotensin-converting enzyme inhibition on sodium handling in patients with advanced chronic obstructive pulmonary disease.

Authors:  M O Farber; M H Weinberger; G L Robertson; N S Fineberg
Journal:  Am Rev Respir Dis       Date:  1987-10

7.  Noninvasive measurement of blood flow and extraction fraction.

Authors:  A M Peters; R D Gunasekera; B L Henderson; J Brown; J P Lavender; M De Souza; J M Ash; D L Gilday
Journal:  Nucl Med Commun       Date:  1987-10       Impact factor: 1.690

8.  Hypoxaemia in chronic obstructive bronchitis.

Authors:  H C Middleton; M D Peake; P Howard
Journal:  Thorax       Date:  1979-04       Impact factor: 9.139

9.  Angiotensin-II acts centrally to alter renal sympathetic nerve activity and the intrarenal renin-angiotensin system.

Authors:  L B Weekley
Journal:  Cardiovasc Res       Date:  1991-05       Impact factor: 10.787

10.  The effects of stimulating carotid chemoreceptors on renal haemodynamics and function in dogs.

Authors:  F Karim; S M Poucher; R A Summerill
Journal:  J Physiol       Date:  1987-11       Impact factor: 5.182

View more
  5 in total

1.  Vasopressin and oxytocin release during prolonged environmental hypoxia in the rat.

Authors:  H Kelestimur; R M Leach; J P Ward; M L Forsling
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

2.  Association Between Serum Sodium and Long-Term Mortality in Critically Ill Patients with Comorbid Chronic Obstructive Pulmonary Disease: Analysis from the MIMIC-IV Database.

Authors:  Liming Fan; Deyang Sun; Jia Yang; Xiawei Shi; Fenglin Shen; Ke Chen; Junchao Yang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-05-12

3.  Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.

Authors:  Shweta Bansal; David Badesch; Todd Bull; Robert W Schrier
Journal:  Contemp Clin Trials       Date:  2009-04-16       Impact factor: 2.226

4.  Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes.

Authors:  Paul R Forfia; Anjali Vaidya; Susan E Wiegers
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

Review 5.  Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony.

Authors:  Aibek E Mirrakhimov
Journal:  Cardiovasc Diabetol       Date:  2012-10-27       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.